var data={"title":"Chloroprocaine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Chloroprocaine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5871?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=chloroprocaine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Chloroprocaine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=chloroprocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Chloroprocaine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149713\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Nesacaine;</li>\n      <li>Nesacaine-MPF</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149730\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Local Anesthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149716\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Local anesthesia:</b> Use the smallest dose and concentration required to produce the desired result. Dosage varies with anesthetic procedure, the vascularity of the tissues, depth of anesthesia required, degree of muscle relaxation required, duration of anesthesia, and physical condition of the patient. Use reduced doses in debilitated patients and patients with cardiovascular disease. During epidural administration, a test dose (3 mL of 3% <b>or</b> 5 mL of 2%) is recommended prior to induction of complete block and all reinforcing doses with continuous catheter technique.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Clorotekal:</i> Subarachnoid block (spinal anesthesia): Intrathecal: 1%: 50 mg single dose (effective block to the T 10 level). <b>Note:</b> Other preservative- and antioxidant-free formulations (eg, Nesacaine-MPF) have also been used off-label (dosage range: 20 to 60 mg) for spinal anesthesia for short-duration ambulatory procedures; ensure that preservative-free products do not contain the antioxidant sodium bisulfite prior to administration (Gebhardt 2017; Hejtmanek 2011; Yoos 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Nesacaine, Nesacaine-MPF:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maximum single dose (without epinephrine): 11 mg/kg; maximum total dose: 800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maximum single dose (with epinephrine 1:200,000): 14 mg/kg; maximum total dose: 1,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Caudal block: Preservative free: 2% or 3%: 15 to 25 mL; may repeat at 40- to 60-minute intervals</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infiltration and peripheral nerve block:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Digital (without epinephrine): 1%; 3 to 4 mL; total dose: 30 to 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infraorbital: 2%: 0.5 to 1 mL; total dose 10 to 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mandibular: 2%: 2 to 3 mL; total dose 40 to 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Paracervical: 1%; 3 mL per each of four sites; total dose: up to 120 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pudendal: 2%; 10 mL each side; total dose: 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lumbar epidural anesthesia for Cesarean delivery: Preservative free: 3%: 15 to 25 mL total dose (includes test dose of 2 or 3 mL) (Abboud 1983; Bjornestad 2006; Chestnut 2014; Feng 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lumbar epidural anesthesia, non-parturient: Preservative-free: 2% or 3%: 2 to 2.5 mL per segment; usual total volume: 15 to 25 mL; may repeat with doses that are 2 to 6 mL less than initial dose every 40 to 50 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149724\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=chloroprocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Chloroprocaine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Local anesthesia:</b> Use the smallest dose and concentration required to produce the desired result. Dosage varies with anesthetic procedure, the vascularity of the tissues, depth of anesthesia required, degree of muscle relaxation required, duration of anesthesia, and physical condition of the patient. Use reduced doses in debilitated patients and patients with cardiovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Children &gt;3 years (normally developed) and Adolescents: Maximum dose (without epinephrine): 11 mg/kg; for infiltration, concentrations of 0.5% to 1% are recommended; for nerve block, concentrations of 1% to 1.5% are recommended</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149717\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Dosage should be reduced; refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682597\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution due to increased risk of adverse effects. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682598\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; however, dosage should be reduced. Use with caution due to increased risk of adverse effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149695\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nesacaine: 1% (30 mL); 2% (30 mL) [contains disodium edta, methylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nesacaine-MPF: 2% (20 mL); 3% (20 mL) [methylparaben free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2% (20 mL); 3% (20 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149680\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50663866\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Clorotekal: FDA approved September 2017; anticipated availability is currently unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149697\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Infiltration or peripheral nerve block:</b> Administer locally as a single injection or continuously through an indwelling catheter (peripheral nerve block). Avoid rapid injection. Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Epidural (thoracic, lumbar, or caudal) and subarachnoid block (spinal anesthesia): Do not use solutions containing preservatives. </b>Use a filter needle to draw up solution from ampule when using Clorotekal. Do not puncture areas of the skin with signs of infection/inflammation. Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided. Clorotekal is intended for intrathecal administration only; the manufacturer recommends against using for epidural administration. Use of Clorotekal via continuous spinal catheters is not recommended (safety has not been established).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149696\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Local anesthesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chloroprocaine (with preservatives):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Production of local anesthesia by infiltration and peripheral nerve block.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chloroprocaine (without preservatives):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Production of local anesthesia by infiltration and peripheral nerve block, as well as epidural and caudal administration; production of local anesthesia by subarachnoid block (spinal anesthesia) in adults (Clorotekal only).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Due to chloroprocaine&rsquo;s fast onset and short duration of action, it is most often used to establish adequate epidural anesthesia (eg, in a parturient prior to delivery) or possibly, for peripheral nerve block in a patient undergoing short (&lt;60 minutes) ambulatory surgery that is not anticipated to produce significant postoperative pain (Alley 2014; Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Nesacaine, Nesacaine-MPF: The manufacturer recommends against using either formulation (ie, with or without preservatives) for subarachnoid administration (ie, spinal anesthesia); however, the use of chloroprocaine without preservatives (Nesacaine-MPF) has been safely used off-label for spinal anesthesia (Goldblum 2013; Miller 2010; Yoos 2005). Do not use chloroprocaine with preservatives (Nesacaine) for epidural or spinal anesthesia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149737\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nesacaine may be confused with Neptazane</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149687\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Central nervous system: Procedural pain (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperglycemia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site pain (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia, syncope, ventricular arrhythmia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety, dizziness, increased body temperature, loss of consciousness, restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis, erythema, pruritus, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylactoid reaction, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Chondrolysis (continuous intra-articular administration)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Laryngeal edema, respiratory arrest, sneezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Akathisia, anaphylaxis, arachnoiditis, auditory impairment, back pain, burning sensation, cardiac arrhythmia, cardiac insufficiency, cardiac arrest, cauda equine syndrome, diplopia, drowsiness, dysesthesia, dyspnea, erythema multiforme, fecal incontinence, feeling hot, groin pain, hypertension, hypoesthesia, limb pain, localized numbness (perineal; causing sexual dysfunction), malaise, motor dysfunction, myocardial depression, myoclonus, oral hypoesthesia, oral paresthesia, paresthesia, peripheral neuropathy, photophobia, presyncope, prolonged emergency from anesthesia, respiratory arrest, respiratory depression, seizure, sexual disorder, speech disturbance, spinal cord injury, tachycardia, tremor, urinary incontinence, urinary retention, visual disturbance, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149700\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to chloroprocaine, other para aminobenzoic acid (PABA) ester type anesthetics, or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications described in the Clorotekal labeling (clinically, some may be applicable to other products): Contraindications specific to spinal anesthesia (eg, decompensated cardiac insufficiency, hypovolemic, shock, coagulopathy); IV regional anesthesia; serious cardiac conduction problems; local infection at the site of proposed lumbar puncture; septicemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149684\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Local anesthetics, at high systemic concentrations, are commonly associated with hypotension and bradycardia especially with inadvertent intravascular administration. Perform preventive measures (eg, limiting cumulative dose, use ultrasound or direct visualization for catheter placement). Careful and constant monitoring of the patient's cardiovascular vital signs should be done during and following each local anesthetic injection (Cox 2003; Dickerson 2014). In the event of cardiovascular collapse and/or severe CNS toxicity, treatment in accordance with the American Society of Regional Anesthesia and Pain Medicine&rsquo;s Checklist for Treatment of Local Anesthetic Toxicity is recommended (Neal [ASRA 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Use extreme caution in patients with existing neurological disease. Seizures due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection. In the event of cardiovascular collapse and/or severe CNS toxicity, treatment in accordance with the American Society of Regional Anesthesia and Pain Medicine&rsquo;s Checklist for Treatment of Local Anesthetic Toxicity is recommended (Neal [ASRA 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is <b>not</b> an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory effects: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest. Careful and constant monitoring of the patient's respiratory (adequacy of ventilation) vital signs should be done following each local anesthetic injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use extreme caution in patients with cardiovascular disease, including severe hypertension, hypotension, heart block, and severe cardiac decompensation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with extreme caution in patients with myasthenia gravis; may cause significant weakness (Haroutiunian 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Plasma cholinesterase disorders: Use with caution in patients with genetic deficiency of plasma cholinesterase.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acutely ill patients: Use with caution in acutely ill; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use with caution in debilitated patients; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use with caution in children; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Epidural (thoracic, lumbar, or caudal) and intrathecal/spinal administration: <b>Do not use solutions containing preservatives. </b>Use extreme caution in patients with spinal deformities, neurologic disease, septicemia, and severe hypertension when used for thoracic, lumbar, and caudal epidural administration. With intrathecal/spinal administration, neurologic damage may occur after anesthesia (eg, paresthesia, loss of sensitivity, motor weakness, paralysis, cauda equina syndrome); symptoms may persist and may be permanent; carefully evaluate patients with underlying neuromuscular disorders while considering risk vs. benefit prior to treatment. Use with caution or avoid epidural or intrathecal/spinal administration in patients with bleeding disorders (congenital or acquired) and severe anemia (Horlocker 2010). Clorotekal (a product with specific FDA approval for intrathecal/spinal administration) is contraindicated in patients with serious cardiac conduction abnormalities, local infection at proposed lumbar puncture site, or septicemia; contraindications to intrathecal/spinal anesthesia should be taken into consideration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299021\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149689\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9245&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists: Chloroprocaine may enhance the hypertensive effect of Alpha-/Beta-Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of Bupivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with local anesthetics. Liposomal bupivacaine may be administered 20 minutes or more after the administration of lidocaine, but the optimal duration of dose separation for other local anesthetics is unknown<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: Chloroprocaine may enhance the hypertensive effect of Ergot Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylephrine (Systemic): Chloroprocaine may enhance the hypertensive effect of Phenylephrine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonamide Antibiotics: Chloroprocaine may diminish the therapeutic effect of Sulfonamide Antibiotics.  Management: Avoid concurrent use of chloroprocaine and systemic sulfonamide-based antimicrobials whenever possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149691\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149702\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Local anesthetics rapidly cross the placenta and may cause varying degrees of maternal, fetal, and neonatal toxicity. Close maternal and fetal monitoring (heart rate and electronic fetal monitoring advised) are required during obstetrical use. Maternal hypotension has resulted from regional anesthesia. Positioning the patient on her left side and elevating the legs may help. Epidural, paracervical, or pudendal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts. The use of some local anesthetic drugs during labor and delivery may diminish muscle strength and tone for the first day or two of life. Administration as a paracervical block is not recommended with toxemia of pregnancy, fetal distress, or prematurity. Administration of a paracervical block early in pregnancy has resulted in maternal seizures and cardiovascular collapse. Fetal bradycardia and acidosis also have been reported. Fetal depression has occurred following unintended fetal intracranial injection while administering a paracervical and/or pudendal block.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20613555\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if chloroprocaine is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149693\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Cardiovascular and respiratory status; mental status; vital signs; signs of CNS toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149683\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Chloroprocaine is an ester-type local anesthetic, which stabilizes the neuronal membranes and prevents initiation and transmission of nerve impulses thereby affecting local anesthetic actions. Chloroprocaine reversibly prevents generation and conduction of electrical impulses in neurons by decreasing the transient increase in permeability to sodium. The differential sensitivity generally depends on the size of the fiber; small fibers are more sensitive than larger fibers and require a longer period for recovery. Sensory pain fibers are usually blocked first, followed by fibers that transmit sensations of temperature, touch, and deep pressure. High concentrations block sympathetic somatic sensory and somatic motor fibers. The spread of anesthesia depends upon the distribution of the solution. This is primarily dependent on the volume of drug injected.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149699\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: 6 to 12 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration (patient, type of block, concentration, and method of anesthesia dependent): Up to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Depends upon route of administration; high concentrations found in highly perfused organs such as liver, lungs, heart, and brain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Rapidly hydrolyzed by plasma enzymes to 2-chloro-4-aminobenzoic acid and beta-diethylaminoethanol (80% conjugated before elimination)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: In vitro, plasma: Neonates: 43 &plusmn; 2 seconds; Adults: 21 &plusmn; 2 seconds (males), 25 &plusmn; 1 second (females)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (minimal as unchanged drug in urine; metabolites: Chloro-aminobenzoic acid and beta-diethylaminoethanol primarily excreted unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323059\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Chloroprocaine HCl (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (20 mL): $25.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3% (20 mL): $26.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nesacaine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (30 mL): $21.65</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (30 mL): $22.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nesacaine-MPF Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (20 mL): $25.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3% (20 mL): $26.86</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038558\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ampres (GB);</li>\n      <li>Ivracain (CH);</li>\n      <li>Nesacaine (CH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abboud TK, Kim KC, Noueihed R, et al. Epidural bupivacaine, chloroprocaine, or lidocaine for cesarean section--maternal and neonatal effects. <i>Anesth Analg</i>. 1983;62(10):914-919.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/6614524/pubmed\" target=\"_blank\" id=\"6614524\">6614524</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alley EA, Mulory MF. Neuraxial anesthesia for outpatients. <i>Anesthesiol Clin</i>. 2014;32(2):357-369. doi: 10.1016/j.anclin.2014.02.007.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/24882123/pubmed\" target=\"_blank\" id=\"24882123\">24882123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bj&oslash;rnestad E, Iversen OL, Raeder J. Similar onset time of 2-chloroprocaine and lidocaine + epinephrine for epidural anesthesia for elective Cesarean section. <i>Acta Anaesthesiol Scand</i>. 2006;50(3):358-363.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/16480471/pubmed\" target=\"_blank\" id=\"16480471\">16480471</a>]</span><span class=\"doi\">10.1111/j.1399-6576.2006.00937.x</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chestnut DH, Wong CA, Tsen LC, Ngan Kee WD, Beilin Y, Mhyre JM. <i>Chestnut's Obstetric Anesthesia: Principles and Practice</i>. 5th ed. Philadelphia, PA: Elsevier Saunders; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clorotekal (chloroprocaine) [prescribing information]. Mendrisio, Switzerland: Sintetica SA; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coda B, Bausch S, Haas M, et al, &ldquo;The Hypothesis That Antagonism of Fentanyl Analgesia by 2-Chloroprocaine Is Mediated by Direct Action on Opioid Receptors,&rdquo; <i>Reg Anesth</i>, 1997, 22(1):43-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/9010946/pubmed\" target=\"_blank\" id=\"9010946\">9010946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corke BC, Carlson CG, and Dettbarn WD, &ldquo;The Influence of 2-Chloroprocaine on the Subsequent Analgesic Potency of Bupivacaine,&rdquo; <i>Anesthesiology</i>, 1984, 60(1):25-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/6691592/pubmed\" target=\"_blank\" id=\"6691592\">6691592</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cox B, Durieux ME, Marcus MA. Toxicity of local anaesthetics. <i>Best Pract Res Clin Anaesthesiol</i>. 2003;17(1):111-136.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/12751552/pubmed\" target=\"_blank\" id=\"12751552\">12751552</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dickerson DM, Apfelbaum JL. Local anesthetic systemic toxicity. <i>Aesthet Surg J</i>. 2014;34(7):1111-1119. doi: 10.1177/1090820X14543102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/25028740/pubmed\" target=\"_blank\" id=\"25028740\">25028740</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dix SK, Rosner GF, Nayar M, et al, &ldquo;Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,&rdquo; <i>Crit Care Med</i>, 2011, 39(4):872-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/21263316/pubmed\" target=\"_blank\" id=\"21263316\">21263316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feng SW, Cao Y, Wang WG, Liu YS, Shen XF. Addition of adrenaline to chloroprocaine provides a moderate duration time for epidural anaesthesia in elective caesarean section. <i>J Int Med Res</i>. 2012;40(3):1099-1107. doi: 10.1177/147323001204000329.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/22906283/pubmed\" target=\"_blank\" id=\"22906283\">22906283</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freeman DW and Arnold NI, &ldquo;Paracervical Block With Low Doses of Chloroprocaine: Fetal and Maternal Effects,&rdquo; <i>JAMA</i>, 1975, 231(1):56-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/1243568/pubmed\" target=\"_blank\" id=\"1243568\">1243568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gebhardt V, Mueller-Hansen L, Schwarz A, Bussen D, Weiss C, Schmittner MD. Chloroprocaine 10 mg/ml for low-dose spinal anaesthesia in perianal surgery - a randomised dose finding study. <i>Acta Anaesthesiol Scand</i>. 2017;61(2):241-249. doi: 10.1111/aas.12839.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/27892594/pubmed\" target=\"_blank\" id=\"27892594\">27892594</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldblum E, Atchabahian A. The use of 2-chloroprocaine for spinal anaesthesia. <i>Acta Anaesthesiol Scand</i>. 2013;57(5):545-552. doi: 10.1111/aas.12071.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/23320599/pubmed\" target=\"_blank\" id=\"23320599\">23320599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haroutiunian S, Lecht S, Zur AA, et al The challenge of pain management in patients with myasthenia gravis. <i>J Pain Palliat Care Pharmacother</i>. 2009;23(3):242-260.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/19670021/pubmed\" target=\"_blank\" id=\"19670021\">19670021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hejtmanek MR, Pollock JE. Chloroprocaine for spinal anesthesia: a retrospective analysis. <i>Acta Anaesthesiol Scand</i>. 2011;55(3):267-272. doi: 10.1111/j.1399-6576.2010.02371.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/21288208/pubmed\" target=\"_blank\" id=\"21288208\">21288208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). <i>Reg Anesth Pain Med</i>. 2010;35(1):64-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/20052816/pubmed\" target=\"_blank\" id=\"20052816\">20052816</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jankowsky EC, &ldquo;Pharmacologic Aspects of Local Anesthetic Use,&rdquo; <i>Anesth Clin North Am</i>, 1990, 8:1-25.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, eds. <i>Miller's Anesthesia</i>. 7th ed. London, Englad: Churchill Livingstone; 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neal JM, Mulroy MF, Weinberg GL; American Society of Regional Anesthesia and Pain Medicine. American Society of Regional Anesthesia and Pain Medicine checklist for managing local anesthetic systemic toxicity: 2012 version. <i>Reg Anesth Pain Med</i>. 2012;37(1):16-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/22189574/pubmed\" target=\"_blank\" id=\"22189574\">22189574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nesacaine and Nesacaine-MPF (chloroprocaine) [prescribing information]. Schaumburg, IL: APP Pharmaceuticals; July 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoos JR, Kopacz DJ. Spinal 2-chloroprocaine for surgery: an initial 10-month experience. <i>Anesth Analg</i>. 2005;100(2):553-558. doi: 10.1213/01.ANE.0000130397.38849.4A.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloroprocaine-drug-information/abstract-text/15673893/pubmed\" target=\"_blank\" id=\"15673893\">15673893</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9245 Version 100.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F149713\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F149730\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F149716\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F149724\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F149717\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15682597\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682598\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F149695\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F149680\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50663866\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F149697\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F149696\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F149737\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F149687\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F149700\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F149684\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299021\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F149689\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F149691\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F149702\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20613555\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F149693\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F149683\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F149699\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323059\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038558\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9245|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=chloroprocaine-patient-drug-information\" class=\"drug drug_patient\">Chloroprocaine: Patient drug information</a></li><li><a href=\"topic.htm?path=chloroprocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">Chloroprocaine: Pediatric drug information</a></li></ul></div></div>","javascript":null}